Vivos Therapeutics, Inc.
VVOS
$2.63
-$0.08-2.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -11.14M | -12.57M | -12.04M | -15.64M | -13.58M |
| Total Depreciation and Amortization | 581.00K | 586.00K | 589.00K | 592.00K | 621.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 804.00K | 1.20M | -519.00K | 695.00K | -1.85M |
| Change in Net Operating Assets | -2.94M | -1.72M | 862.00K | 3.43M | 2.86M |
| Cash from Operations | -12.69M | -12.50M | -11.11M | -10.92M | -11.95M |
| Capital Expenditure | -568.00K | -568.00K | -530.00K | -715.00K | -853.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -568.00K | -568.00K | -530.00K | -715.00K | -853.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 19.24M | 19.74M | 15.44M | 7.94M | 12.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.36M | -1.35M | -838.00K | -738.00K | -1.08M |
| Cash from Financing | 17.88M | 18.39M | 14.60M | 7.20M | 10.92M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4.62M | 5.32M | 2.96M | -4.44M | -1.88M |